Pertuzumab
Navigation Links
Pertuzumab in Medical News
...tuzumab in the Metastatic Setting also finds that Genentech/Roche/Chugai's pertuzumab in combination with Herceptin and Sanofi Aventis' Taxotere will become Deci...rug analysis using our proprietary drug comparator model, we concluded that pertuzumab will have competitive advantages in efficacy when used in combination with ...
...ytic leukemia, Medarex/Bristol-Myers Squibb's ipilimumab for malignant myeloma, Genmab's zanolimumab for T-cell lymphoma, and Genentech/Roche/Chugai's pertuzumab for breast cancer. "These emerging MAbs will contribute significant sales by 2016," said Clair Gricks, Ph.D., analyst at Decision Resources, "They w...
...ytic leukemia, Medarex/Bristol-Myers Squibb's ipilimumab for malignant myeloma, Genmab's zanolimumab for T-cell lymphoma, and Genentech/Roche/Chugai's pertuzumab for breast cancer. "These emerging MAbs will contribute significant sales by 2016," said Clair Gricks, Ph.D., analyst at Decision Resources, "They w...
Experimental drug boosts survival in recurrent ovarian cancer
...w clinical data showed an experimental drug called pertuzumab prolonged the survival time for women with recurre...hija said Phase II clinical trial data showed that pertuzumab added weeks to the lives of Stage 3 ovarian cancer...h existing chemotherapy regimens. In the study, pertuzumab was administered in combination with a standard ch...New Drugs Shows Promise in Slowing the Progression of Prostate Cancer
... time,” said Agus. “Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be v...Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cance...d ovarian cancer. In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkag...New Drug Promises Prolonged Survival in Prostate Cancer Patients
... time,” said Agus. “Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be v...Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cance...ed ovarian cancer. In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkag...Pertuzumab in Medical Technology
Investigational cancer drug Pertuzumab shows promising results in
advanced breast cancer when combined with Herceptin Phase III
development initiated
BASEL, Switzerland, June 4, 2007-Early clinical results from
Roche's trial of the exciting new cancer medicine pertuzumab, a HER
dimerisation inhibi...
New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
... will be presented on the investigational drug pertuzumab which will highlight the benefits that pertuzumab in combination with Herceptin could offer to patients with advanced breast cancer. pertuzumab is the first of a new, innovative class of tar...Other TagsRethinkScreenedLymphomLymphomLymphomdonedonePregnancPregnancPregnancChildsTanTanTanTanTanTanTanTanOther Contentspectoralpedigreepedigreegirdlepelvicpelvicpelvicpelvicpelvicpeptidespeptidespeptidespeptidespeptidespeptidespeptidesgroovegroovegroove
(Date:11/28/2009)...hange after 30-minute psychosocial intervention, s...y News) -- A program that gets persistent drunk dr...rous behavior may lead to significant and long-las... study included 184 men and women with two or more...omly assigned to one of two interventions. The fir...
(Date:11/27/2009)...s Ltd. today issued its latest biochemical analysi...he lethality of the virus has dropped from its pea...break in the spring of 2009 to resting non-epidemi...ectivity count, however, remains increased. , ...009 -- Biotech firm Replikins Ltd., which has anal...
(Date:11/27/2009)...ewswire-FirstCall/ -- Shamir Optical Industry Ltd.... of innovative products and technology to the opht... of directors had declared a dividend distribution...mately NIS 37.62 million based on the November 25,...mately US$ 0.609 (approximately NIS 2.3 based on t...
(Date:11/27/2009)...announced today that Spectrum Health (Grand Rapids...orthopedic templating solution and its TraumaCad E... (PRWEB) November 27, 2009 -- Voyant Health&trade...ds, Michigan) has licensed its TraumaCad Enterpris... Extend workflow solution, to allow its orthopedic...
(Date:11/26/2009)...ire/ -- The diabetes population in the United Stat...nnual medical spending on the disease is projected...according to a study published in the December iss...betes ® Program (NCDP), a program of Novo Nor... University of Chicago. ,, According to the for...
Breaking Medicine News(10 mins):Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4[1] Drunk Drivers May Respond to Brief Motivational Interview[0] Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased[0] Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend[0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend[1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
(Date:11/24/2009)...ease is available in Spanish . , The presen...els of inflammatory substances in the blood, hinde...wn by a research project of the University of Nava...tist at the School of Pharmacy. , The project, e...relation to the control of body weight and inflamm...
(Date:11/23/2009)...n, D.C. The community-associated strain of the de...sistant to most common antibioticsposes a far grea...ing its way into hospitals, according to a study i...ses . , The new threat is easily picked up in f...nd has increased the overall burden of MRSA within...
(Date:11/23/2009)..., November 23, 2009 - The time of day matters to f...ew paper produced by a research team led by Profes...rough,s vice-principal for research and colleagues...the St. George campus. , Capitalizing on their...tree, the research team examined how poplar trees ...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2New study finds MRSA on the rise in hospital outpatients 2Time of day matters to thirsty trees, U of T researcher discovers 2Cell Therapeutics Inc 28CTI 29 to Present at 8th Annual BIO Investor Forum 5673 1MedAppz Signs Agreement with MedAssets to Offer SAAS based Electronic Health Record to MedAssets 26apos 3B Non acute Customers 60045 1MedAppz Signs Agreement with MedAssets to Offer SAAS based Electronic Health Record to MedAssets 26apos 3B Non acute Customers 60045 2Wellcome Trust funds dengue fever research in Leuven 10516 1Wellcome Trust funds dengue fever research in Leuven 10516 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |